Refine by
Heart Function Articles & Analysis
33 news found
Bodyport’s focus on the patient has driven them to create an incredibly simple solution for patients with congestive heart failure. The Bodyport solution will reduce common monitoring complexities for patients while advancing how clinicians manage their patients,” Pursley said. ...
This innovative solution enables people with fluid management conditions, such as heart failure and kidney disease, to noninvasively assess measures of heart function and fluid status in the same step they take to measure their weight. ...
Bodyport, a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. The scales can detect these signals through the feet when a patient steps onto the device. ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with ...
– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. ...
Lipman’s appointment comes as Bodyport prepares for commercialization of its proprietary Bodyport Cardiac Scale™, an innovative technology that remotely and noninvasively assesses heart function and fluid status in people living with fluid management conditions. ...
Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. Barostim works by stimulating baroreceptors - natural sensors in the body that tell the nervous system how to regulate heart, kidney and vascular function. These effects reduce ...
ByCVRx
“The published results from our clinical trials to date [3], [4]. [5],[6], [7] have met our high expectations in showing the therapy’s ability to address the loss of heart function in ischemic heart failure. We look forward to completing our Phase III trial and engaging with the FDA as we move closer to the prospect of benefiting ...
Kosmos’ AI-driven system enables automated assessment of systolic heart function at bedside and is the only “hybrid” device in its category to provide diagnostic-quality scans while also meeting HIPAA requirements for data collection, storage, and transmission. Kosmos is rapidly emerging as a tool of choice for cardiologists and critical care ...
RVOT reconstruction is a procedure needed to correct certain congenital heart defects. Following implantation, Xeltis’ synthetic restorative pulmonary heart valves evolve into fully functioning, natural heart valves through colonization by the patient’s own tissue. The implants’ porous micro-structure enables ...
Studies have shown that the DynamX Bioadaptor improves vessel function in several ways.9 It enables the vessel to accommodate disease progression and achieve positive adaptive remodeling by increasing vessel area and maintaining lumen diameter, which preserves blood flow to the heart. DynamX restores vessel function and allows for normal vessel ...
The benefits of restored vessel function may provide greater benefit in patients with complex disease. ...
These patients are in a life-threatening condition: their health has deteriorated so much that they desperately need a new heart, but because of their poor end-organ function, amongst other issues, their chances to survive on the waiting list are low. ...
“We are very pleased that the InEK continues to support patient access to our innovative LIVE Therapy, which published studies have shown improves heart function, patient symptoms, activity level and quality of life for patients with scarred hearts after a heart attack,” said BioVentrix CEO Ken Miller LIVE™ ...
This has been shown to (a) maintain the ability for positive adaptive remodeling, (b) restore vessel function, and (c) allow for the vessel’s return towards baseline angulation. ...
Estep specializes in managing advanced heart failure patients and is the Head of the Section of Heart Failure and Transplantation in the Tomsich Family Department of Cardiovascular Medicine in the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the prestigious Cleveland Clinic. ...
This has been associated with effects on the heart, lung and brain function. “Such studies are invaluable, but consistently remind us that designing out and preventing occupational exposures is easier, and likely to have a longer-term benefit for our health, than trying to monitor exposures and find cures for the illnesses that they cause,” comments ...
This has been associated with effects on the heart, lung and brain function. “Such studies are invaluable, but consistently remind us that designing out and preventing occupational exposures is easier, and likely to have a longer-term benefit for our health, than trying to monitor exposures and find cures for the illnesses that they cause,” comments ...
Hanover, Germany, October 22, 2020 - Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, ...
” Last year BIOLIFE4D successfully demonstrated the ability to 3D bioprint its prototype mini-heart, a scaled down version of a native human heart with limited functionality, and is now focused on refining its technology as it aims for commercialization – particularly with significant potential within applications for COVID-19 ...